<DOC>
	<DOC>NCT00497159</DOC>
	<brief_summary>This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.</brief_summary>
	<brief_title>A Study of the Novel Drug Dimebon in Patients With Huntington's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD; Able to take medication (capsules) by mouth. Clinical evidence of unstable medical illness; Females who are pregnant or lactating or who intend to become pregnant during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Trial of Dimebon to treat patients with mild-to-moderate Huntington's disease.</keyword>
</DOC>